eli lilly glp-1 agonist Medscape Administration Anounces Landmark GLP-1 Pricing
Description
2012 Nov;98(2):271-84
Undisclosed ingredients
Despite media narratives that often frame GLP-1 drugs as empowering, over half of women (52%) and more than a third of men (37%) believe users are judged negatively, seen as taking the easy way out
Let's talk about that
Understanding the lack of improved cardiovascular outcomes with GLP-1R agonists in ELIXA, EXSCEL, PIONEER 6, and FREEDOM CVOTs is complex, potentially originating from differences in trial design, variable sample sizes, discontinuation rates, follow-up durations, and challenges in achieving sustained pharmacokinetics during drug development
Capehorn, M
